Tradestie Institutional Equity Comparison Engine
NTLA vs BHVN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BHVN Overall Edge
BHVN Captures Institutional Edge (3โ0 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biohaven Ltd. (BHVN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NTLA trades at N/M Forward P/E with -826.0% operating margin (-48.0% YoY revenue) versus BHVN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro) against BHVN sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
NTLA N/M vs BHVN N/M Fwd P/E
Growth & Margin Winner
BHVN
Op Margin -826.0% vs 0.0% ยท YoY -48.0% vs +0.0%
Momentum & Technical Winner
BHVN
1Y +12.5% vs +72.6% ยท 52W Pos 17% vs 59%
Options & Structure Winner
BHVN
BREAKDOWN (78th %ile IV) vs CONSOLIDATION (18th %ile IV)
NTLA
NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$9.75
+0.52% 1D
Market Cap
$1.5B
1M Return
-14.62%
1Y Return
+12.46%
Forward P/E
N/M
Unified AI Score
50.7 / 100
HOLD
Tech 47.0
Fund 55.0
Flow 59.0
Mom 60.0
BHVN
NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.95
+0.9% 1D
Market Cap
$2.1B
1M Return
+29.36%
1Y Return
+72.59%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 15.0
Fund 42.0
Flow 68.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NTLA +12.46%
BHVN +72.59%
Spread: +60.13 pp (BHVN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
NTLA TTM Op. Margin: -826.0%
BHVN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NTLA vs BHVN. Trailing 12-month operating profitability (NTLA -826.0% vs BHVN 0.0%) and valuation multiples (NTLA N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NTLA | BHVN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.5B | $2.1B | Larger Scale | BHVN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -48.0% | +0.0% | Higher Growth | BHVN |
| Operating Margin (TTM) Profitability | -826.0% | 0.0% | Higher Margin | BHVN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -62.6% | -799.5% | Higher ROE | NTLA |
| 52-Week Range Position Momentum | 17% ($8โ$18) | 59% ($8โ$18) | Stronger Trend | BHVN |
| Beta / 30D Volatility Risk Regime | 2.29ฮฒ ยท 88% Vol | 1.40ฮฒ ยท 111% Vol | Lower Realized Risk | NTLA |
| Unified Institutional Score Composite Signal | 50.7 / 100 (HOLD) | 42.1 / 100 (HOLD) | Higher Composite | NTLA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NTLA vs BHVN Buy Guide
NTLA
BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
78th %ile
IV Regime
Elevated (60thโ80th %ile)
BHVN
CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
18th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NTLA nor BHVN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.